PubMed · 9281066
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M Ricchetti, H Buc. 1997-08-15. Telomerase activity of reverse transcriptase.. https://doi.org/10.1126/science.277.5328.883f
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Islatravir (EFdA) is a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI) that potently blocks HIV-1 replication in vivo. Its unique structural features in contrast to nucleoside reverse transcriptase inhibitors (NRTIs), particularly the 4'-ethynyl and 3'-hydroxy groups, contribute to its high clinical potency. Once intracellularly activated to EFdA 5'-triphosphate (EFdA-TP), it competes with dATP for incorporation by HIV-1 reverse transcriptase (RT) during HIV-1 genomic replication. The 4'-ethynyl group of incorporated EFdA-MP interacts with a hydrophobic pocket of HIV-1 RT, hindering DNA translocation and terminating DNA synthesis. The M184V mutation, commonly associated with resistance to NRTIs such as lamivudine and emtricitabine, and the M184V/A114S mutations, both located within the hydrophobic pocket, were shown to reduce Islatravir susceptibility in cell-based viral resistance selection assays. To elucidate the mechanisms by which these mutations affect Islatravir inhibition, we employed pre-steady-state kinetics to investigate their impact on EFdA-TP incorporation by HIV-1 RT using both DNA and RNA templates. We found that M184V had a modest effect on EFdA-TP incorporation efficiency, increasing it 2-fold with the DNA template and decreasing it 3-fold with the RNA template. In contrast, M184V/A114S significantly inhibited EFdA-TP incorporation, reducing its incorporation efficiency 5.4-fold with the DNA template and 181-fold with the RNA template. These reductions were primarily attributable to corresponding decreases in EFdA-TP incorporation rate constants of 18-fold and 105-fold, respectively. These results suggest that, unlike FDA-approved NRTIs, the clinical efficacy of Islatravir, may not be substantially compromised by the M184V mutation alone but will be significantly reduced by the M184V/A114S mutations.
The enantioselective synthesis of the beta-d (1) enantiomer of 4'-C-ethynyl-2',3'-dideoxycytidine confirms an earlier stereochemical assignment that was strictly based on the ability of HIV reverse transcriptase and its M184V mutant to discriminate between the d- and l-configuration of nucleoside 5'-triphosphates.
Water and 80% ethanol extracts of 20 Thai medicinal plants used to treat AIDS were tested for their HIV type 1 reverse transcriptase inhibitory activity. The water extracts of Ipomoea carnea subsp. fistulosa (aerial parts), Vitex glabrata (branch), Vitex trifolia (aerial part), Vitex negundo (aerial part), Canna indica (rhizome), and Justicia gendarussa (aerial part) showed HIV-1 RT inhibition ratio (% IR) higher than 90% at a 200 microg/ml concentration. The water extract of Canna indica rhizomes (IC(50) 22.56 microg/ml) was selected for further study, i.e. for its HIV-1 RT inhibition activity and the purification and characterization of the active proteins. Proteins in water extract were fractionated by ammonium sulfate precipitation and separated by sodium dodecyl sulfate acrylamide gel electrophoresis (SDS-PAGE), yielding two proteins, Cip31 (31 kDa) and Cip14 (14 kDa) with IC50 of 17.41 and 19.25 microg/ml and isoelectric point (pI) of 3.5 and 6.35, respectively. Both proteins showed significant HIV-1 RT inhibition.